922 related articles for article (PubMed ID: 26547257)
41. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
42. The role of phototherapy in cutaneous T-cell lymphoma.
Pothiawala SZ; Baldwin BT; Cherpelis BS; Lien MH; Fenske NA
J Drugs Dermatol; 2010 Jul; 9(7):764-72. PubMed ID: 20677530
[TBL] [Abstract][Full Text] [Related]
43. Mycosis fungoides and sezary syndrome: an update.
Kim EJ; Lin J; Junkins-Hopkins JM; Vittorio CC; Rook AH
Curr Oncol Rep; 2006 Sep; 8(5):376-86. PubMed ID: 16901399
[TBL] [Abstract][Full Text] [Related]
44. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
45. How I treat mycosis fungoides and Sézary syndrome.
Whittaker S; Hoppe R; Prince HM
Blood; 2016 Jun; 127(25):3142-53. PubMed ID: 27151889
[TBL] [Abstract][Full Text] [Related]
46. Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study.
Ahmad K; Rogers S; McNicholas PD; Collins P
Acta Derm Venereol; 2007; 87(5):413-7. PubMed ID: 17721648
[TBL] [Abstract][Full Text] [Related]
47. Ultraviolet A1 phototherapy for mycosis fungoides.
Olek-Hrab K; Silny W; Dańczak-Pazdrowska A; Osmola-Mańkowska A; Sadowska PA; Polańska A; Gniadecki R; Jenerowicz D
Clin Exp Dermatol; 2013 Mar; 38(2):126-30. PubMed ID: 23082901
[TBL] [Abstract][Full Text] [Related]
48. [Combined therapy of psoralen plus ultraviolet A followed by narrow band ultraviolet B photochemotherapy for early stage mycosis fungoides].
Wang T; Liu Y; Zheng H; Zuo Y; Fang K
Zhonghua Zhong Liu Za Zhi; 2014 Aug; 36(8):626-8. PubMed ID: 25430032
[TBL] [Abstract][Full Text] [Related]
49. Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.
Vural S; Akay BN; Botsalı A; Atilla E; Parlak N; Okçu Heper A; Şanlı H
Turk J Haematol; 2018 Mar; 35(1):35-41. PubMed ID: 28533196
[TBL] [Abstract][Full Text] [Related]
50. The efficacy and safety of phototherapy in geriatric patients: a retrospective study.
Bulur I; Erdogan HK; Aksu AE; Karapınar T; Saracoglu ZN
An Bras Dermatol; 2018; 93(1):33-38. PubMed ID: 29641694
[TBL] [Abstract][Full Text] [Related]
51. Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach.
Horwitz SM; Olsen EA; Duvic M; Porcu P; Kim YH
J Natl Compr Canc Netw; 2008 Apr; 6(4):436-42. PubMed ID: 18433609
[TBL] [Abstract][Full Text] [Related]
52. Plaque stage mycosis fungoides treated with bexarotene at low dosage and UVB-NB.
D'Acunto C; Gurioli C; Neri I
J Dermatolog Treat; 2010 Jan; 21(1):45-8. PubMed ID: 19603308
[TBL] [Abstract][Full Text] [Related]
53. Phototherapy for cutaneous T-cell lymphoma: online survey and literature review.
Carter J; Zug KA
J Am Acad Dermatol; 2009 Jan; 60(1):39-50. PubMed ID: 18842323
[TBL] [Abstract][Full Text] [Related]
54. [Mycosis fungoides and Sézary syndrome : a systematic review].
André F; Guenova E; Blanchard G
Rev Med Suisse; 2022 Mar; 18(775):578-589. PubMed ID: 35353453
[TBL] [Abstract][Full Text] [Related]
55. Mycosis fungoides and the Sézary syndrome.
Kim YH; Hoppe RT
Semin Oncol; 1999 Jun; 26(3):276-89. PubMed ID: 10375085
[TBL] [Abstract][Full Text] [Related]
56. Mycosis Fungoides and Sézary Syndrome: An Update.
Larocca C; Kupper T
Hematol Oncol Clin North Am; 2019 Feb; 33(1):103-120. PubMed ID: 30497668
[TBL] [Abstract][Full Text] [Related]
57. Risk of skin cancers in mycosis fungoides patients receiving PUVA therapy: A real-life experience from a single tertiary center.
Doğan PE; Akay BN; Vural S; Arı C; Yılmaz TE; Şanlı H
Photodermatol Photoimmunol Photomed; 2023 Sep; 39(5):428-434. PubMed ID: 36967646
[TBL] [Abstract][Full Text] [Related]
58. [Treatment of mycosis fungoides and Sézary syndrome].
Nicolay JP; Assaf C
Hautarzt; 2017 Sep; 68(9):702-710. PubMed ID: 28770285
[TBL] [Abstract][Full Text] [Related]
59. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer.
Olsen EA; Whittaker S; Kim YH; Duvic M; Prince HM; Lessin SR; Wood GS; Willemze R; Demierre MF; Pimpinelli N; Bernengo MG; Ortiz-Romero PL; Bagot M; Estrach T; Guitart J; Knobler R; Sanches JA; Iwatsuki K; Sugaya M; Dummer R; Pittelkow M; Hoppe R; Parker S; Geskin L; Pinter-Brown L; Girardi M; Burg G; Ranki A; Vermeer M; Horwitz S; Heald P; Rosen S; Cerroni L; Dreno B; Vonderheid EC; ; ;
J Clin Oncol; 2011 Jun; 29(18):2598-607. PubMed ID: 21576639
[TBL] [Abstract][Full Text] [Related]
60. A practical approach to accurate classification and staging of mycosis fungoides and Sézary syndrome.
Thomas BR; Whittaker S
Skin Therapy Lett; 2012 Dec; 17(10):5-9. PubMed ID: 23223768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
